期刊
JOURNAL OF CLINICAL VIROLOGY
卷 46, 期 -, 页码 S73-S76出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jcv.2009.07.002
关键词
Cytomegalovirus vaccine; Glycoprotein B; Congenital CMV infection; MF59
类别
资金
- NCRR NIH HHS [M01 RR000032-475082, M01 RR000032-450691, M01 RR000032-460691, M01 RR000032, M01 RR000032-400678, M01 RR00032, M01 RR000032-440691] Funding Source: Medline
- NIAID NIH HHS [U01 AI063565-03, P01 AI043681-05, P01 AI043681-02, U01 AI063565, U01 AI063565-05, U01 AI063565-01, P01 AI043681, P01 AI043681-05S1, P01 AI043681-03, U01 AI063565-06, P01 AI043681-040001, U01 AI063565-02, P01 AI043681-050001, P01 AI043681-020001, P01 AI043681-010001, P01 AI043681-04, U01 AI063565-04, P01 AI043681-030001] Funding Source: Medline
A vaccine comprised of recombinant cytomegalovirus (CMV) envelope glycoprotein B (gB) with MF59 adjuvant developed in the 1990s recently was recently found to have efficacy for prevention of CMV infection in a phase 2 clinical trial in young mothers. This review briefly considers the rationale for gB as a vaccine antigen, the history of this CMV gB vaccine and the data supporting vaccine efficacy. (c) 2009 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
